Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T24715 |
RLX
THA-Q,PD-139530,THA Q,PD 139530,PD139530 |
||
RLX is a PI3K/Akt/FoxO3a signaling inhibitor in experimental colon cancer. | |||
T62929 |
RLX-33
|
ERK; RXFP receptor | GPCR/G Protein; MAPK |
RLX-33 是一种有效的、选择性的、能够透过血脑屏障的松弛素家族肽 3 (RXFP3) 拮抗剂,也能够阻断松弛素 3 (relaxin 3) 诱导的 ERK1/2 磷酸化。RLX-33 作用于 RXFP3、ERK1 和 ERK2 磷酸化的 IC50 分别为 2.36 μM、7.82 μM 和 13.86 μM。RLX-33 可以阻断 RXFP3 选择性激动剂 R3/I5 诱导的大鼠食物摄取增加。RLX-33 能够用于研究代谢综合征。 | |||
T36404L |
PRLX-93936 HCL
PRLX-93936 hcl(903499-49-0 Free base) |
Ferroptosis; Reactive Oxygen Species | Apoptosis; Immunology/Inflammation; Metabolism; NF-κB |
PRLX-93936 HCL 是 erastin 的类似物,并显示出与顺铂对非小细胞肺癌 (NSCLC) 细胞的协同作用。 | |||
T36404 |
PRLX-93936
|
||
PRLX-93936 is an analog of erastin that has antitumor activity. It inhibits the hypoxia-inducible factor 1 (HIF-1) signaling pathway under hypoxic conditions (IC50 = 0.09 μM in a cell-based reporter assay). PRLX-93936 (1 μM) also inhibits hypoxia-induced increases in HIF-1α expression in ME-180 cervical cancer cells. It inhibits the growth of HT-1080 fibrosarcoma, OVCAR-5 ovarian cancer, BJELR tumorigenic primary fibroblast, and PANC-1 pancreatic cancer cells with IC50 values of less than 100 nM... |